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Abstract
There are many markers for the risk assessment of cardiovascular diseases. New sensitive and specific biomarkers 
that could help stratify risk, in both healthy and cardiovascular populations, are still being sought. Galectin 3 and ST-2 
seem to be very promising molecules. However, further research is needed to establish their full diagnostic and prog-
nostic value. We present a review of the literature showing the possibility of comprehensive use of both biomarkers, 
especially in coronary artery disease. Galectin-3 and ST-2, through their association with fibrotic processes, may prove 
to be beneficial in patients with coronary disease and following myocardial infarction.
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Introduction
Cardiovascular diseases (CVD) belong to the group of chron-
ic diseases usually developing throughout life. CVDs are the 
most common cause of death in Poland (46%) and at the 
same time they are characterized by increasing morbidity 
[1]. Therefore, it is important to have indicators to improve 
the diagnostic process of CVD at different stages of the 
disease, and prognosis of risk level. The most common 
CVD is coronary artery disease. Proven indicators in the 
assessment of the initial stages of atherosclerosis include: 
IMT, intima–media thickness, PMV, pulse wave velocity, 
ABI, ankle-brachial index, assessing all types of serum 
cholesterol fractions. However, the evaluation of troponin 
dynamics is a key element in the diagnosis of myocardial 
necrosis [2, 3]. Recently there has been an increased 
interest in new biochemical markers. Consistent evidence 
from prospective studies is needed if we wanted to add 
them to the new diagnostic algorithms.
The following paper summarises current knowledge on 
the characteristics and potential use of galactin 3 (Gal-3) 
and ST-2 protein (suppression of tumorigenicity 2) in car-
diology, especially in coronary artery disease.
Biological characteristics of Gal-3 
and ST-2 proteins
Gal-3 is a representative of galectins belonging to the 
family of carbohydrate-binding proteins (lectins) [4, 5]. It 
has a domain structure consisting of: a short N-terminal 
domain, collagen-like and atypical C-terminal domain within 
which there is a carbohydrate recognizing domain (CRD), 
thanks to which Gal-3 interacts with a significant number 
of ligands, e.g. receptors located on the cell surface, as 
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well as with extracellular space proteins, modulating in-
tercellular adhesion [4, 6] (Figure 1). It is found mainly in 
the cytoplasm, while its expression occurs in many types 
of cells, including macrophages, neutrophils, fibroblasts, 
cancer cells, and is involved in inflammatory responses 
and the fibrosing processes [4, 5].
The ST-2 protein belongs to the superfamily of Toll 
receptors binding interleukin 1 (TIR, Toll/interleukin-1 re-
ceptor) [7]. It has two clinically significant forms - trans-
membrane and soluble. The transmembrane form (ST-2L, 
ST-2 ligand) is present mainly on inflammatory cells, car-
diomyocytes and endothelium. Animal studies have shown 
that interleukin 33 (IL-33) interacts with ST-2L present on 
cardiomyocytes to prevent myocardial hypertrophy and 
fibrosis [7]. The soluble form (sST-2, soluble ST-2) circu-
lates freely in the blood and it is possible to measure its 
concentration in a standard biochemical blood test [7, 8]. 
The release of sST-2 is regulated by fibroblasts which are 
stimulated for growth and by pro-inflammatory cytokines, 
e.g. tumour necrosis factor α (TNF-α) and interleukin 6 (IL-6) 
[8]. Excessive concentration of sST-2 prevents the binding 
of IL-33 to the ST-2L protein, contributing to the occurrence 
of adverse changes in the heart structure [8]. It is said that 
IL-33/ST-2 interaction, apart from participation in fibrosis 
and myocardial remodeling also takes part in atheroscle-
rosis progression [8] (Figure 2).
New perspectives for the use  
of biomarkers in clinical practice
Coronary artery disease
The role of inflammatory process in the pathogenesis 
of atherosclerosis is emphasized. Currently, sensitive 
inflammatory biomarkers are being searched for, which 
could help in early and effective identification of patients 
with increased risk of coronary artery disease, as well as 
to predict responses to treatment and assess prognosis. 
Myocardial infarction (MI) leads to myocardial necrosis 
and structural and biochemical changes in damaged tis-
sues. These changes include deposition of collagen with 
scarring, fibrosis, hypertrophy and a change in the volume 
of the heart cavities, which is referred to as remodeling 
and leads to the development of heart failure. It is worth 
emphasizing that post-infarct remodeling also involves 
tissues which did not undergo ischemia with the aim of 
maintaining systolic and diastolic heart function [9].
According to the nationwide AMI-PL database (Nationwi-
de Acute Myocardial Infarction Database in Poland), nearly 
80% of patients with ST-elevation myocardial infarction 
(STEMI) are subjected to coronary revascularization [10]. 
Improved treatment of acute coronary syndromes with 
percutaneous coronary intervention (PCI) reduces in-
-hospital mortality however, also leaves a large group of 
patients with left ventricular injury [3]. According AMI-PL 
database, in patients after MI, heart failure was one of the 
most frequent cause of repeated hospitalizations [10].
The role of Gal-3 in coronary artery disease
Gal-3 concentration is significantly higher in patients with 
coronary artery disease, in which an inflammatory substrate 
is one of the main causes of macrophage activation [11]. 
In addition, Gal-3 can affect the development of athero-
sclerotic plaques by preventing the effective removal of 
low-density lipoproteins (LDL) [12]. It is known that Gal-3 
expression is clearly marked in unstable atherosclerotic 
plaques [11]. The role of Gal-3 in the development of 
atherosclerosis is supported by the results of both in vivo 
and in vitro studies. MacKinnon et al. demonstrated that 
Figure 1. Structure of galectin 3 (Gal-3) (based on [6]); CRD — car-
bohydrate recognition domain
C-terminal CRD domain  
(≈ 120 amino acids)
N-terminal domain  
(short, ≈ 30 amino acids)
A naturally occurring ligand for  
the Gal-3 receptor, e.g. laminin
Collagen-like domain  
(≈ 100 amino acids)
Figure 2. Structure of transmembrane and soluble form of ST-2 
(sST-2) protein and the mechanism of their action. Increased sST-2 
concentration prevents the binding of interleukin 33 (IL-33) to the 
ST-2 ligand (ST-2L) protein, contributing to adverse changes in the 
heart structure
Activation of pathological processes: myocardial 
fibrosis, progression of atherosclerosis
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pharmacological blocking of Gal-3 in a mouse significantly 
inhibited the development of atherosclerotic plaque [13].
In experimental studies, a higher expression of 
Gal-3 mRNA was observed in the early post-infarction 
period, with the maximum reached during the first week, 
and a gradual decrease in the following weeks. The con-
centration of Gal-3 also increased in the surrounding 
tissues which were not directly affected by ischemia, in 
which the maximum expression was already reached on 
day 1 [14]. An increase in Gal-3 concentration in the early 
post-infarction period seems to contribute to the activa-
tion of repair functions in the damaged zone in order to 
preserve the geometry and function of the heart [15]. 
However, in the longer term, chronic activation leads to 
tissue fibrosis and accelerated unfavourable remodeling 
of the heart [15]. 
In a study conducted by Tsai et al. of a 196 group of 
patients with acute STEMI showed that Gal-3 concentration 
increases in the first hours after PCI and is an independent 
prognostic factor of death and development of heart failure 
in the early (30-day) post-infarction period, regardless of the 
severity of coronary artery lesions, left ventricular ejection 
fraction (LVEF) and serum creatinine concentration [16]. 
However, it should be noted that Gal-3 is an important 
biomarker of fibrosis, and its expression also increases in 
the course of cirrhosis or progressive kidney fibrosis. De-
terioration of renal function in the course of heart failure 
may have a significant effect on Gal-3 concentration, which 
may affect its prognostic value [17].
In the study carried out by Szadkowska et al. [18], 
patients after MI with elevated Gal-3 concentration during 
hospitalization were characterized by a higher risk of de-
veloping heart failure and atrial fibrillation (AF) de novo. 
However, the authors did not observe correlation between 
the concentration of Gal-3 and LVEF after MI, whereas 
such correlation was documented for N-terminal pro-B-
-type natriuretic peptide (NT-proBNP) and high-sensitivity 
C-reactive protein (hsCRP) [18].
In a study conducted by Weir and his team in a group 
of 100 patients after STEMI, each patient had a Gal-3 con-
centration measurement and magnetic resonance imaging 
(MRI) of the heart at the beginning of the study and after 
4 months. There was no correlation between Gal-3 concen-
tration, LVEF and left ventricular volumes assessed in MRI 
initially, but the reverse correlation between Gal-3 and LVEF 
was observed after 4 months of observation. Moreover, 
throughout the study a correlation between Gal-3 and NT-
-proBNP concentrations and extracellular matrix proteins 
such as matrix metalloproteinase 3 (MMP-3), tissue inhi-
bitor of matrix metalloproteinases 1 (TIMP-1), monocyte 
chemoattractant protein 1 (MCP-1) and interleukin-8 (IL-
8) was observed [19]. In the same group, a correlation 
between a higher Gal-3 concentration and more intensive 
remodeling was observed in patients with preserved LVEF 
(referred to as LVEF > 49. 2%), in the early post-infarction 
period, but not in patients with severe left ventricular dys-
function [19]. In a study carried out by van der Velde et al. 
[20], the concentration of Gal-3, evaluated immediately 
after MI, predicted the LVEF value and the size of post-
-infarction scar after 4 months [20].
To sum up, there is a link between Gal-3 concentration 
and the increased risk of developing heart failure after 
MI. However, due to the small groups participating in the 
studies and the short observation time, the conclusions of 
the studies so far are still limited.
The role of ST-2 protein  
in coronary artery disease
The role of ST-2 protein was also studied in ischemic heart 
disease. It is believed that by assessing the ST-2 protein it 
is possible to predict cardiovascular prognosis, including 
the risk of death in patients with coronary artery disease, 
although its diagnostic use is limited. 
Seki et al. have shown that IL-33 binding to the trans-
membrane form of ST-2 causes activation of the nuclear 
factor (NF)-κB, thanks to which it can regulate the survival 
of cells [21]. In a rat study, subcutaneous injection of IL-
33 resulted in inhibition of apoptosis induced by ischemia 
through increased expression of proteins responsible for 
apoptosis inhibition and decreased activation of caspase 
3, an enzyme which increases the process of apoptosis. 
This led to a decrease in the volume of MI and fibrosis [21].
In addition, it is considered that IL-33/ST-2 protein 
pathway is associated with the pathogenesis of atheroscle-
rosis. It is believed that active inflammation is the cause 
of instability of some atherosclerotic lesions, leading to 
rupture of the plaque and subsequent formation of clots, 
leading to vessel closure and MI. One of the strategies of 
inhibiting the inflammatory process in vessels in the course 
of atherosclerosis may be an increased share of Th2 im-
mune cells. The IL-33/ST2 system can be one of the ways 
leading to their activation. Mice without apolipoprotein E 
gene, fed a high-fat diet have high serum cholesterol levels 
and develop atherosclerosis. Mice treated with IL-33 sho-
wed a reduced number of atherosclerotic plaques and 
lower levels of serum antibodies to oxidized LDL compared 
to control mice. On the other hand, after the initial supply 
of soluble ST-2 form, even before exposure to IL-33, these 
mice showed increased arteriosclerosis in comparison 
to those untreated with sST2 (effect of anti-IL-33 soluble 
isoform ST2) (Figure 3) [7].
By reducing the concentration of interferon γ, IL-
33 stimulates macrophages to produce metalloproteina-
ses (MMPs), prevents the destruction of the extracellular 
matrix and atherosclerotic plaque destabilization [22]. 
The concentration of MMPs is particularly high in the 
acute phase of MI [22]. Guzel et al. [23] found that serum 
IL-33 concentration is significantly lower in patients with 
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non-ST-elevation myocardial infarction (NSTEMI) than in the 
control group and correlates negatively with MMP-9 level. 
An increase in sST-2 and a parallel decrease in IL-33 con-
centration [23] during MI may indicate an increased degree 
of myocardial injury. 
Many studies have shown that the soluble form of 
ST-2 is an important biomarker after MI [21, 24, 25]. The 
sST-2 concentration increases several hours after MI. It 
has been observed that the counteraction to the protec-
tive properties of IL-33 depends on the concentration of 
sST-2 [21]. Moreover, Richards et al. [24] team observed 
that early assessment of sST-2 concentration has the best 
prognostic value. Shimpo et al. [25] proved assessment 
sST-2 in patients after acute STEMI has a predictive value. 
Patients with higher sST-2 serum levels had a significantly 
higher risk of death or occurrence of newly diagnosed he-
art failure within 30 days [25], although this relationship 
lost relevance when B-type natriuretic peptide (BNP) and 
cardiac troponin I (cTnI) () were included in multivariate 
analysis [25]. Jenkins et al. [26] in a study of 1400 patients 
after MI assessed the predictive value in long-term, 5-year 
observation. Elevated sST-2 concentrations were found in 
half of patients with MI, and higher concentrations were 
associated with a high risk of death and development of 
heart failure regardless of other predictors, such as age, 
gender, co-morbidities, troponin T, or Killip class [26]. This 
indicates the need for further research to assess the use-
fulness of ST-2 in predicting the risk of developing heart 
failure after MI.
Interestingly, the CLARITY-TIMI 28 study (CLopidogrel as 
Adjunctive ReperfusIon TherapY-Thrombolysis in Myocardial 
Infarction 28) of patients after STEMI proved that ST-2 pro-
tein is an independent prognostic factor and adding it to 
TIMI Risk Score improves prognostic evaluation of patients 
after STEMI. Sabatine and colleagues showed that the 
combination of ST-2 protein with NT-proBNP significantly 
improves risk stratification in coronary artery disease [27]. 
On the contrary, no improvement in risk stratification was 
demonstrated after including of ST-2 protein to the GRACE 
scale in patients after NSTEMI [28].
Weir et al. [29] observed that in patients after acute 
MI sST-2 concentrations were positively correlated with the 
extent of MI and predicted unfavourable left ventricular 
remodeling evaluated by MRI during 24-week observation. 
The change in sST-2 concentration (evaluated initially and 
after 24 weeks) was associated with a significant change 
in left ventricular end-diastolic volume [29]. sST-2 has not 
been shown to predict for the recurrence of MI [24].
The role of biomarkers  
in other clinical situations
It has been demonstrated that higher Gal-3 concentra-
tions are associated with a higher risk of AF development 
in a 10-year observation period, regardless of age and 
gender [30]. However, this relationship was not observed 
after taking into account other typical risk factors of AF 
development [30]. Elevated Gal-3 levels were also ob-
served in patients with persistent AF without coexisting 
structural heart disease [31]. However, it is still unclear 
whether the Gal-3 assessment may be helpful in iden-
tifying those patients with AF in whom pulmonary venous 
isolation surgery would bring the greatest benefits [31, 
32]. Controversial data also concern the assessment of 
the risk of recurrence of arrhythmia after ablation [31, 
32]. Chen and his team studied the sST-2 concentrations 
in patients with AF not associated with mitral stenosis or 
valvular prosthesis and in patients with sinus rhythm. They 
Figures 3. Interleukin 33 (IL-33)/ST2 system reduces the progression of atherosclerosis (based on [7]); sST-2 — soluble ST-2
Developed atherosclerotic  
plaque
The right wall  
of the vessel
High-fat diet
High-fat diet  
+ IL-33
High-fat diet sST-2  
+ IL-33
More severe atherosclerotic  
lesionsLess severe atherosclerotic  
lesions
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observed higher sST-2 concentrations in patients with AF, 
and a positive correlation with left atrial size. There were 
no differences between patients with paroxysmal and 
persistent AF. During a 6-month observation period, they 
demonstrated that sST-2 and left atrial size are indepen-
dent factors of heart failure development in patients with 
so-called non-valvular AF [33]. 
On the basis of numerous studies the importance of 
ST-2 and Gal-3 proteins in chronic and acute heart failure 
have been proven. This was reflected in the guidelines of 
the American Heart Association (AHA), in which ST-2 and 
Gal-3 proteins were recognized as valuable additional 
diagnostic and prognostic markers in acute and chronic 
heart failure (recommendation class IIb, proof level B) [34]. 
The predictive power of both biomarkers has been shown 
to increase in combination with NT-proBNP. Furthermore, 
heart failure therapy strategies based on measurements 
of several biomarkers can bring additional benefits. 
In a multicentre Framingham Heart Study, sST-2 con-
centration increased with age and was associated with 
higher blood pressure, more frequent use of hypotensive 
drugs and more frequent coexistence of diabetes [35]. 
Higher ST-2 protein concentrations were also observed 
in patients with aortic stenosis [36]. The natural course 
of this heart defect leads to overload of the left ventricle 
and its hypertrophy, and then to fibrosis and remodeling 
of the heart muscle. Sundl and his team evaluated the 
relationship between sST-2 concentrations measured 
before transcatheter aortic valve implantation (TAVI) and 
the prognosis [37]. The baseline sST-2 > 29 ng/ml con-
centration has been shown to be associated with unfavo-
urable prognosis after TAVI procedure and may be useful 
in predicting short and long-term mortality. However, the 
sST-2 protein did not show any advantage over NT-proBNP 
or currently used surgical risk assessment algorithms 
(EuroSORE II, STS_PROM) [37]. 
Wojciechowska et al. [38] demonstrated that ST-2 prote-
in may be useful in the assessment of prognosis in patients 
with dilated cardiomyopathy. Moreover, in hypertrophic 
myocardial model or during active myocardial inflammation 
there is a significant infiltration of activated macrophages 
with increased Gal-3 concentrations [39]. The MADIT-CRT 
(Multicenter Automatic Implantation Trial With Resynchro-
nization Therapy) subanalysis evaluated the benefit of car-
diac resynchronization therapy in patients with symptoms 
of low severity heart failure (I–II class of New York Heart 
Association [NYHA]) depending on Gal-3 concentration. It 
was shown that patients with higher Gal-3 concentrations 
benefited more from this therapy [40]. The authors suggest 
that elevated Gal-3 concentration in this subgroup of pa-
tients with heart failure indicates the ongoing processes 
of fibrosis, which means that these patients may respond 
better to cardiac resynchronization therapy (CRT) therapy 
and its anti-fibrosis properties as well as the process of 
myocardial remodeling [40].
New therapeutic perspectives
Assuming that Gal-3 and ST-2 protein are associated with 
the risk of developing post-infarction heart failure, it may 
be hypothesized that the use of treatments to reduce 
unwanted remodeling of the heart, such as angiotensin-
-converting enzyme inhibitors, sartans or aldosterone 
receptor antagonists, may be particularly beneficial in 
patients with increased concentrations of these markers 
after MI. Importantly, it has been demonstrated that the 
prevention of unfavourable myocardial remodeling due 
to eplerenone is more strongly expressed in patients 
with high sST-2 concentration [41]. In addition, there are 
reports that it is possible to inhibit the progression of 
heart failure by pharmacological or genetic blocking of 
biomarkers, which gives an additional perspective on the 
use of metabolic pathways of these proteins in the the-
rapy of heart failure [7, 42]. There are also data showing 
better response to statin therapy in patients with lower 
Gal-3 concentrations [17].
Summary
The need to extend diagnostic algorithms has initiated 
many studies on new markers. Numerous studies and 
publications present the possibility of comprehensive use 
of Gal-3 and ST-2 protein. It has been shown that Gal-3 
and ST-2 protein, due to their connection with fibrosing 
processes, may turn out to be the key markers in patients 
with coronary artery disease and post MI. It is suggested 
that Gal-3 in the initial stages after MI contributes to proper 
tissue repair, but over time its excessive activation leads 
to unfavourable remodeling of the left ventricle. The ST-2 
protein can provide valuable predictive information on 
the risk of developing heart failure. In addition, there are 
reports of the use of new biomarkers to evaluate prognosis 
after TAVI treatment or to predict the benefits of resynchro-
nization therapy. Pharmacological or genetic potential for 
interference in the pathways of both molecules is being 
studied. However, due to small groups of patients and 
relatively short observation time, conclusions from these 
studies are limited.
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Streszczenie
Istnieje wiele markerów oceny ryzyka chorób sercowo-naczyniowych. Wciąż poszukuje się nowych czułych i specyficznych 
biomarkerów, które mogłyby pomóc w stratyfikacji ryzyka zarówno wśród populacji zdrowej, jak i obciążonej chorobami 
sercowo-naczyniowymi. Galektyna 3 oraz białko ST-2 wydają się być niezwykle obiecującym wskaźnikami, niemniej 
jednak potrzeba dalszych badań nad tymi cząsteczkami do poznania ich pełnej wartości diagnostyczno-prognostycznej. 
W pracy prezentujemy badania i publikacje przedstawiające możliwość wszechstronnego wykorzystania obu biomarke-
rów, zwłaszcza w chorobie wieńcowej. Galektyna 3 oraz białko ST-2, poprzez swój związek z procesami włóknienia, mogą 
okazać się kluczowymi markerami u pacjentów z chorobą wieńcową oraz po zawale serca.
Słowa kluczowe: białko ST-2, choroby sercowo-naczyniowe, choroba wieńcowa, galektyna 3, remodeling, zawał serca
Folia Cardiologica 2019; 14, 1: 60–66
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